Capricor Therapeutics, Inc.
0 products tracked · names used in filings: Capricor Therapeutics, Inc.
Upcoming milestones
Deramiocel: PDUFA target action date (Duchenne muscular dystrophy (DMD))
Capricor Therapeutics, Inc. (CAPR); BLA; status: extended; "Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update ● Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 ● Major BLA amendment added two-year open-label extension (OLE)…"; filed 2026-11-10 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.